The ZegeneX 2026 New York Venture Summit presentation will take place November 18–19, 2026, at the Javits Center in New York City, following the company's selection to present at the event. There, ZegeneX will introduce ZGX5 (Zegen-X5), an investigational, shelf-stable topical small-molecule therapeutic in preclinical development for diabetic foot ulcers (DFUs), to investors, biotech leaders and potential partners.
Key Highlights
- Event: New York Venture Summit 2026, November 18–19, New York City
- Product: ZGX5 (Zegen-X5), an investigational small-molecule topical therapeutic
- Target: Diabetic foot ulcers
- Stage: Preclinical; not approved for any use
Why This Milestone Matters
The New York Venture Summit brings together venture capitalists, corporate investors and early-stage company leaders. Presenting there gives ZegeneX a platform to share its wound-care biotechnology, which grew out of University of Pittsburgh research using zebrafish.
ZGX5 and the Chronic Wound Challenge
Diabetic foot ulcers are open sores that can stall instead of healing, and non-healing ulcers can lead to infections and other serious complications. ZGX5 is designed to address impaired healing by targeting biological signaling pathways in the body's natural wound-healing process.
Why Shelf-Stable Wound Care Matters
Many biologic wound-care products need cold-chain storage. ZGX5's shelf-stable formulation is designed to stay stable at ambient temperatures, which could make a future therapy easier to store and distribute if it holds up through clinical development.
What's Next
ZegeneX continues its preclinical work on ZGX5. Investors, researchers and partners can connect with the team at zegenex.com.
Frequently Asked Questions
What is the 2026 New York Venture Summit?
An investor and startup event on November 18–19, 2026, at the Javits Center in New York City.
What is ZGX5?
ZGX5 (Zegen-X5) is ZegeneX's investigational, shelf-stable topical small-molecule therapeutic for chronic wounds, starting with diabetic foot ulcers.
Is ZGX5 approved to treat diabetic foot ulcers?
No. It is in preclinical development, and its safety and effectiveness in humans have not been established.
What does shelf-stable mean?
The product is designed to stay stable at ambient temperatures, without the refrigeration many biologics require.
Related reading: Partnerships & Investor Relations | ZegeneX clinical pipeline | Chronic Wound Treatment Options Compared
Medical disclaimer: ZGX5 is an investigational therapeutic in preclinical development and is not an approved treatment. This article is for information only and is not medical advice.
Translational Innovation from the University of Pittsburgh
ZegeneX Therapeutics is advancing first-in-class small-molecule regenerative wound healing therapeutics licensed from the University of Pittsburgh to eliminate avoidable diabetic amputations worldwide.
